Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis

[Image: see text] There is an urgent need for new treatments for visceral leishmaniasis (VL), a parasitic infection which impacts heavily large areas of East Africa, Asia, and South America. We previously reported on the discovery of GSK3494245/DDD01305143 (1) as a preclinical candidate for VL and,...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Michael, Brand, Stephen, De Rycker, Manu, Zuccotto, Fabio, Lukac, Iva, Dodd, Peter G., Ko, Eun-Jung, Manthri, Sujatha, McGonagle, Kate, Osuna-Cabello, Maria, Riley, Jennifer, Pont, Caterina, Simeons, Frederick, Stojanovski, Laste, Thomas, John, Thompson, Stephen, Viayna, Elisabet, Fiandor, Jose M., Martin, Julio, Wyatt, Paul G., Miles, Timothy J., Read, Kevin D., Marco, Maria, Gilbert, Ian H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154566/
https://www.ncbi.nlm.nih.gov/pubmed/33904304
http://dx.doi.org/10.1021/acs.jmedchem.1c00047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154566/
https://www.ncbi.nlm.nih.gov/pubmed/33904304
http://dx.doi.org/10.1021/acs.jmedchem.1c00047

Ejemplares similares